This product belongs to the macrolide antibiotics, and its mechanism is to inhibit protein synthesis by hindering the association of 50S subunits of nuclear proteins. This product has an inhibitory effect on Gram-positive bacteria, such as Staphylococcus aureus, Streptococcus, and Pneumococcus, and also has an inhibitory effect on some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Gonorrhea, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, Propionibacterium acnes, etc., and also has an inhibitory effect on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria, such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae, is stronger than erythromycin. There is cross-resistance between this product and erythromycin.

It has a direct relaxant effect on the smooth muscles of the respiratory tract. Its mechanism of action includes inhibiting phosphodiesterase, increasing the intracellular cAMP content; the bronchial dilation effect is partly due to the release of endogenous adrenaline and noradrenaline; as a purine receptor blocker, it can counteract the contraction effect of adenine on the respiratory tract; it enhances the contractility of the diaphragm and improves respiratory function.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.